Destiny Pharma plc
DEST.L · LSE
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.34 | -1.52 | 0.46 | -0.63 |
| FCF Yield | -8.30% | -15.52% | -8.12% | -24.80% |
| EV / EBITDA | -8.70 | -4.21 | -9.28 | -3.25 |
| Quality | ||||
| ROIC | -62.74% | -87.21% | -72.95% | -44.00% |
| Gross Margin | 99.25% | 92.02% | 90.73% | -35.59% |
| Cash Conversion Ratio | 0.92 | 0.90 | 0.95 | 1.00 |
| Growth | ||||
| Revenue 3-Year CAGR | 83.30% | 131.52% | -23.86% | – |
| Free Cash Flow Growth | 9.66% | -14.17% | 33.56% | -67.47% |
| Safety | ||||
| Net Debt / EBITDA | 0.97 | 0.63 | 0.74 | 1.49 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -23,294.26 | -5,108.55 | -6,361.00 | -15,688.73 |